Literature DB >> 12393305

Changes in CREB-phosphorylation during recovery from major depression.

Jakob M Koch1, Susanne Kell, Dunja Hinze-Selch, Josef B Aldenhoff.   

Abstract

For decades psychiatrists have been looking for biological state markers measurable by easy blood test in order to follow up and predict early on treatment response in patients with major depression. In the present study we investigated whether or not measuring CREB (cAMP-response-element-binding-protein) phosphorylation in peripheral blood T lymphocytes is a state marker of treatment response. CREB is an ubiquitous key-element of intracellular signal transduction cascades and its transcriptional activity depends on phosphorylation at Ser-133. Several studies in animals demonstrated that the transcriptional activity of CREB is up-regulated by antidepressant treatment. Therefore, it has been hypothesized that antidepressant treatment exerts its therapeutic effect by this mechanism. In the present study, we investigated CREB-phosphorylation in T-lymphocytes of 20 patients before and in the end of week one and two of either psychopharmacological or psychotherapeutic treatment. After two weeks, 15 patients fulfilled the criteria of treatment response (i.e. 30% reduction in HAMD score compared to baseline), whereas five patients did not. In the end of week two, the responders showed a significant increase in CREB-phosphorylation (P = 0.018) compared to the non-responders. This was true for all patients with either treatment regimen. In conclusion, these results indicate for the first time that the increase in CREB-phosphorylation might be a molecular state marker for the response to antidepressant treatment. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393305     DOI: 10.1016/s0022-3956(02)00056-0

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  11 in total

1.  Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.

Authors:  Yoshihiko Matsumoto; Chiara Fabbri; Silvia Pellegrini; Stefano Porcelli; Pierluigi Politi; Silvio Bellino; Caterina Iofrida; Veronica Mariotti; Erika Melissari; Marco Menchetti; Valentina Martinelli; Marco Cappucciati; Paola Bozzatello; Elena Brignolo; Paolo Brambilla; Matteo Balestrieri; Alessandro Serretti
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

2.  CREB1 gene polymorphisms combined with environmental risk factors increase susceptibility to major depressive disorder (MDD).

Authors:  Peng Wang; Yanjie Yang; Xiuxian Yang; Xiaohui Qiu; Zhengxue Qiao; Lin Wang; Xiongzhao Zhu; Hong Sui; Jingsong Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.

Authors:  J C Felger; S W Cole; T W W Pace; F Hu; B J Woolwine; G H Doho; C L Raison; A H Miller
Journal:  Psychol Med       Date:  2011-12-09       Impact factor: 7.723

Review 4.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

5.  Maternal warmth buffers the effects of low early-life socioeconomic status on pro-inflammatory signaling in adulthood.

Authors:  E Chen; G E Miller; M S Kobor; S W Cole
Journal:  Mol Psychiatry       Date:  2010-05-18       Impact factor: 15.992

6.  Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.

Authors:  Denis J David; Benjamin Adam Samuels; Quentin Rainer; Jing-Wen Wang; Douglas Marsteller; Indira Mendez; Michael Drew; Douglas A Craig; Bruno P Guiard; Jean-Philippe Guilloux; Roman P Artymyshyn; Alain M Gardier; Christophe Gerald; Irina A Antonijevic; E David Leonardo; René Hen
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

7.  Novel antidepressant-like activity of propolis extract mediated by enhanced glucocorticoid receptor function in the hippocampus.

Authors:  Mi-Sook Lee; Young Han Kim; Wan-Soon Park; Won Gyeong Ahn; Ok Kyu Park; Seung-Hae Kwon; Kyoji Morita; Insop Shim; Song Her
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-19       Impact factor: 2.629

8.  Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.

Authors:  Sara Morley-Fletcher; Jerome Mairesse; Amelie Soumier; Mounira Banasr; Francesca Fagioli; Cecilia Gabriel; Elisabeth Mocaer; Annie Daszuta; Bruce McEwen; Ferdinando Nicoletti; Stefania Maccari
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

9.  Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.

Authors:  Francis E Lotrich; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

10.  Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A.

Authors:  Yogesh Dwivedi; Ghanshyam N Pandey
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.